Oncorena Raises 133 Million SEK to Advance Metastatic Kidney Cancer Study Oncorena's latest share issue raised 133 million SEK to support its clinical study ONC175, a promising treatment for metastatic renal cell carcinoma.

Oncorena Raises 133 Million SEK to Advance Metastatic Kidney Cancer Study #Sweden #Lund #Kidney_Cancer #Oncorena #ONC175

Oncorena Achieves Full Subscription of New Share Issuance, Raises 133 Million SEK Oncorena's latest share issuance attracted full subscriptions totaling 133 million SEK, funding crucial cancer drug studies. The future looks promising as investor confidence grows.

Oncorena Achieves Full Subscription of New Share Issuance, Raises 133 Million SEK #Sweden #Lund #Kidney_Cancer #Oncorena #ONC175

Oncorena Receives FDA Approval for Phase I/II Studies in the US for Kidney Cancer Treatment Oncorena has secured FDA approval to start Phase I/II clinical trials for ONC175, a potential treatment for metastatic kidney cancer patients in urgent need.

Oncorena Receives FDA Approval for Phase I/II Studies in the US for Kidney Cancer Treatment #USA #FDA_Approval #Houston #Oncorena #ONC175

Oncorena Gains FDA Approval for Groundbreaking Kidney Cancer Study in the US Oncorena's FDA approval paves the way for its Phase I/II clinical study, offering hope for renal cancer patients in urgent need of new treatments.

Oncorena Gains FDA Approval for Groundbreaking Kidney Cancer Study in the US #USA #Houston #Kidney_Cancer #Oncorena #ONC175